Soliris may induce remission of aHUS in children with anti-FH antibodies

Soliris (eculizumab) can effectively induce and maintain remission of atypical hemolytic uremic syndrome (aHUS) in children with autoantibodies that target complement factor H (FH). That’s according to a study that found the therapy reduced anti-FH antibodies no matter the type of immunosuppressive treatments used with it. They also…

Discontinuing Soliris After aHUS Remission Is Safe, Saves Costs: Study

When treating atypical hemolytic uremic syndrome (aHUS) with Soliris (eculizumab), the medication can be safely discontinued after the immune system disorder is in remission, a new study shows. Moreover, the results suggest that stopping Soliris, rather than continuing treatment indefinitely, can lead to substantial cost savings without notably…

Discontinuing Soliris Is Safe for Certain aHUS Patients

Treatment with Soliris (eculizumab) may be discontinued with close monitoring in people with atypical hemolytic uremic syndrome (aHUS) whose disease is in remission for at least six months — providing their kidney function remains stable — or in those who have developed end-stage kidney disease, a small study…